Table 2 Association between SHON protein cytoplasmic expression and clinicopathological variables in the NUH-ES-BC cohort (n = 1,650)
Variables | SHON protein cytoplasmic expression | χ2 p value (2 sided) | |
|---|---|---|---|
Low N (%) | High N (%) | ||
(A) Pathological parameters | |||
Lymph node (LN) metastases | 0.432 | ||
Negative | 343 (63.2) | 457 (61.0) | |
Positive | 200 (36.8) | 292 (39.0) | |
Gradea | <0.001* | ||
Low (G1) | 102 (18.8) | 106 (14.2) | |
Intermediate (G2) | 192 (35.3) | 213 (28.6) | |
High (G3) | 250 (46.0) | 426 (57.2) | |
Tumour size (cm) | 0.180 | ||
T1 a + b (≤ 1.0) | 49 (9.0) | 80 (10.7) | |
T1 c (> 1.0–2.0) | 286 (52.6) | 286 (38.4) | |
T2 (> 2.0–5.0) | 198 (36.4) | 25 (3.4) | |
T3 (> 5.0) | 11 (2.0) | 25 (3.4) | |
Mitotic index | <0.001* | ||
M1 | 208 (38.9) | 204 (27.6) | |
M2 | 100 (18.7) | 143 (19.3) | |
M3 | 227 (42.4) | 393 (53.1) | |
Pleomorphism | <0.001* | ||
P1 | 13 (2.4) | 15 (2.0) | |
P2 | 229 (42.8) | 240 (32.4) | |
P3 | 293 (54.8) | 485 (65.5) | |
Tubule formation | 0.488 | ||
T1 | 31 (5.8) | 43 (5.8) | |
T2 | 189 (35.3) | 238 (32.2) | |
T3 | 315 (58.9) | 459 (62.0) | |
Lympho-vascular invasion | 0.114 | ||
Positive | 368 (68.8) | 477 (64.5) | |
Negative | 167 (31.2) | 262 (35.5) | |
Histological type of invasive carcinoma | <0.001* | ||
Invasive ductal carcinoma - no special type | 256 (56.6) | 409 (63.7) | |
Tubular carcinoma | 86 (19.0) | 138 (21.5) | |
Medullary carcinoma | 10 (2.2) | 15 (2.3) | |
Invasive lobular carcinoma | 56 (12.4) | 32 (5.0) | |
Others | 44 (9.7) | 48 (7.5) | |
(B) Molecular characteristics | |||
ERα (IHC) | <0.001* | ||
Negative | 117 (21.8) | 224 (33.2) | |
Positive | 419 (78.2) | 490 (66.8) | |
PR (IHC) | 0.048* | ||
Negative | 210 (41.3) | 322 (47.0) | |
Positive | 299 (58.7) | 363 (55.4) | |
HER2 overexpression | 0.008* | ||
No | 485 (91.0) | 624 (86.1) | |
Yes | 48 (9.0) | 101 (13.9) | |
HER3 (IHC) | <0.001* | ||
Negative | 236 (56.7) | 263 (44.9) | |
Positive | 180 (43.3) | 323 (55.1) | |
HER4 (IHC) | 0.006* | ||
Negative | 204 (47.3) | 227 (38.7) | |
Positive | 227 (52.7) | 360 (61.3) | |
Androgen receptor (IHC) | 0.580 | ||
Negative | 156 (37.7) | 229 (39.4) | |
Positive | 258 (62.3) | 352 (60.6) | |
EGFR (IHC) | 0.005* | ||
Low | 335 (83.8) | 442 (76.3) | |
High | 65 (16.3) | 137 (23.7) | |
MIB1 (Ki67) (IHC) | 0.004* | ||
Low | 170 (38.7) | 189 (30.1) | |
High | 269 (61.3) | 438 (69.9) | |
BRCA1 (IHC) | 0.207 | ||
Absent | 65 (18.1) | 114 (21.5) | |
Normal | 295 (81.9) | 416 (78.5) | |
SHON nuclear (IHC) | <0.001* | ||
Negative | 491 (93.3) | 731 (98.8) | |
Positive | 35 (6.7) | 9 (1.2) | |
SPAG5 (IHC) | 0.03* | ||
Low | 321 (82.5) | 417 (76.7) | |
High | 68 (17.5) | 127 (23.3 | |
KIF2C (IHC) | 0.003* | ||
Low | 138 (39.9) | 155 (30.2) | |
High | 208 (60.1) | 358 (69.8) | |
PARP1 (IHC) | 0.008* | ||
Low | 245 (77.8) | 314 (69.2) | |
High | 70 (22.2) | 140 (ki67 | |
TOPO2A (IHC) | 0.360 | ||
Low | 174 (47.5) | 236 (44.4) | |
High | 192 (52.5) | 295 (55.6) | |
P53 (IHC) | 0.121 | ||
Low | 338 (80.9) | 460 (76.8) | |
High | 80 (19.1) | 139 (23.2) | |
P27 (IHC) | 0.997 | ||
Low | 198 (61.1) | 227 (61.1) | |
High | 126 (38.9) | 173 (38.9) | |
Cyclin B2 (IHC) | <0.001* | ||
Low | 288 (54.3) | 295 (39.4) | |
High | 242 (45.7) | 453 (60.6) | |
MDM2 (IHC) | <0.001* | ||
Low | 241 (68.7) | 412 (79.2) | |
High | 110 (31.3) | 108 (20.8) | |
MDM4 (IHC) | 0.002* | ||
Low | 314 (68.0) | 386 (58.8) | |
High | 148 (32.0) | 271 (41.2) | |
P21 (IHC) | 0.064 | ||
Negative | 218 (59.7) | 284 (53.5) | |
Positive | 147 (40.3) | 247 (46.5) | |
P16 (IHC) | 0.274 | ||
Low | 292 (86.1) | 431 (83.4) | |
High | 47 (13.9) | 86 (16.6) | |
P63 (IHC) | 0.925 | ||
Negative | 433 (98.0) | 602 (98.0) | |
Positive | 9 (2.0) | 12 (2.0) | |
CDK1 (IHC) | <0.001* | ||
Low | 219 (77.9) | 307 (65.7) | |
High | 62 (22.1) | 160 (34.3) | |
BCL-2 (IHC) | 0.384 | ||
Low | 159 (33.9) | 240 (36.4) | |
High | 310 (66.1) | 419 (63.6) | |
BAX (IHC) | 0.01* | ||
Low | 209 (74.9) | 282 (65.7) | |
High | 70 (25.1) | 147 (34.3) | |
CK18 (IHC) | 0.77 | ||
Negative | 48 (11.9) | 85 (11.3) | |
Positive | 355 (88.1) | 510 (88.7) | |
CK19 (IHC) | 0.308 | ||
Negative | 31 (7.0) | 34 (5.5) | |
Positive | 411 (93.0) | 585 (4.5) | |
CK14 (IHC) | 0.384 | ||
Negative | 385 (87.7) | 534 (85.9) | |
Positive | 54 (12.3) | 88 (14.1) | |
CK6 (IHC) | 0.039* | ||
Negative | 379 (85.2) | 501 (80.3) | |
Positive | 66 (14.8) | 123 (19.7) | |
SMA (IHC) | 0.036* | ||
Negative | 385 (87.5) | 505 (82.8) | |
Positive | 55 (12.5) | 105 (17.2) | |
ERCC1 (IHC) | 0.081 | ||
Low | 151 (64.5) | 200 (57.3) | |
High | 83 (35.5) | 149 (42.7) | |
TDK (IHC) | 0.407 | ||
Low | 211 (61.2) | 278 (58.3) | |
High | 134 (38.8) | 199 (41.7) | |
RECQL4 cytoplasm (IHC) | <0.001* | ||
Low | 81 (24.3) | 51 (10.1) | |
High | 252 (75.7) | 453 (89.9) | |
RECQL4 nuclear (IHC) | 0.921 | ||
Low | 167 (50.2) | 251 (49.8) | |
High | 166 (49.8) | 253 (50.2) | |
RECQL5 (IHC) | 0.023* | ||
Low | 204 (51.4) | 243 (43.9) | |
High | 193 (48.6) | 310 (56.1) | |
Vimentin (IHC) | 0.637 | ||
Low | 400 (89.1) | 566 (88.2) | |
High | 49 (10.9) | 76 (11.8) | |
E-cadherin (IHC) | 0.223 | ||
Negative | 28 (6.5) | 29 (4.8) | |
Positive | 402 (93.5) | 580 (95.2) | |
BLM cytoplasm (IHC) | <0.001* | ||
Low | 228 (53.6) | 219 (38.8) | |
High | 197 (46.4) | 345 (61.2) | |
BLM nuclear (IHC) | 0.720 | ||
Low | 231 (54.4) | 313 (55.5) | |
High | 194 (45.6) | 251 (44.5) | |
CHK1 (IHC) | 0.210 | ||
Low | 219 (53.9) | 300 (49.9) | |
High | 187 (46.1) | 301 (50.1) | |
ATM cytoplasm (IHC) | 0.922 | ||
Low | 166 (52.7) | 243 (53.1) | |
High | 149 (47.3) | 215 (46.9) | |
ATR (IHC) | 0.011* | ||
Low | 294 (69.7) | 373 (62.0) | |
High | 128 (30.3) | 229 (38.0) | |
CHK2 (IHC) | <0.001* | ||
Low | 187 (55.3) | 215 (42.6) | |
High | 151 (44.7 | 290 (57.4 | |
Phosphorylated CHK1 nuclear (IHC) | 0.217 | ||
Low | 433 (85.7) | 586 (83.1) | |
High | 72 (14.3) | 119 (16.9) | |
Phosphorylated CHK1 cytoplasm (IHC) | <0.001* | ||
Low | 215 (42.6) | 174 (24.7) | |
High | 290 (57.4) | 531 (75.3) | |
XRCC1 (IHC) | 0.546 | ||
Low | 64 (16.8) | 82 (15.4) | |
High | 316 (83.2) | 452 (84.6) | |
DNA polymerase beta (IHC) | <0.001* | ||
Low | 201 (45.4) | 213 (34.2) | |
High | 242 (54.6) | 409 (65.8) | |
DNA PK (IHC) | <0.001* | ||
Low | 176 (46.0) | 154 (28.1) | |
High | 207 (54.0) | 394 (71.9) | |
SMUG1 (IHC) | 0.095 | ||
Low | 124 (36.6) | 203 (42.4) | |
High | 215 (63.4) | 276 (57.6) | |
APE1 (IHC) | <0.001* | ||
Low | 254 (61.5) | 260 (44.3) | |
High | 159 (38.5) | 327 (55.7) | |
FEN1 (IHC) | 0.780 | ||
Low | 261 (73.7) | 368 (72.9) | |
High | 93 (26.3) | 137 (27.1) | |
Phosphorylated c-Jun (IHC) | 0.023* | ||
Low | 209 (50.9) | 253 (43.5) | |
High | 202 (49.1) | 328 (56.5) | |
Phosphorylated JNK (IHC) | 0.280 | ||
Low | 294 (73.3) | 392 (70.1) | |
High | 107 (26.7) | 167 (29.9) | |
Phosphorylated p38 (IHC) | 0.563 | ||
Low | 322 (85.0) | 457 (83.5) | |
High | 57 (15.0) | 90 (16.5) | |
SRC3 (IHC) | 0.08 | ||
Low | 249 (60.6) | 319 (55.0) | |
High | 162 (39.4) | 261 (45.0) | |
S543 (IHC) | 0.866 | ||
Low | 310 (82.2) | 448 (82.7) | |
High | 67 (17.8) | 94 (17.3) | |
ATF2 (IHC) | 0.325 | ||
Low | 204 (51.4) | 277 (48.2) | |
High | 193 (48.6) | 298 (51.8) | |
T24 (IHC) | 0.885 | ||
Low | 261 (75.4) | 384 (75.0) | |
High | 85 (24.6) | 128 (25.0) | |
T71 (IHC) | 0.015* | ||
Low | 237 (55.0) | 293 (47.3) | |
High | 194 (45.0) | 326 (52.7) | |
HAGE (IHC) | 0.949 | ||
Negative | 440 (90.9) | 602 (90.8) | |
Positive | 44 (9.1) | 61 (9.2) | |
TROAP (IHC) | 0.001* | ||
Negative | 216 (62.8) | 241 (50.6) | |
Positive | 128 (37.2) | 235 (49.4) | |
Breast cancer sub-groups | 0.001* | ||
Luminal A | 184 (41.2) | 202 (32.4) | |
Luminal B (Ki67 ≥ 15) | 142 (31.8) | 181 (29.1) | |
Luminal B (HER2+) | 27 (6.0) | 38 (6.1) | |
Non-luminal HER2+ | 21 (4.7) | 62 (10.0) | |
Basal like | 52 (11.6) | 111 (17.8) | |
ERα−/HER2− none basal | 21 (4.7) | 29 (4.7) | |
Basal-like phenotype | 0.003* | ||
No | 463 (89.9) | 583 (84.0) | |
Yes | 52 (10.1) | 111 (16.0) | |
Triple negative phenotype | 0.005* | ||
No | 441 (83.7) | 559 (77.2) | |
Yes | 68 (16.3) | 165 (22.8) | |
